A family are fundraising to help support their toddler who has been diagnosed with a rare genetic disorder that affects her ...

Cohorts 1-3 remain free of cytokine release syndrome CRIS-7-derived CD3 design underpins a controlled T-cell response, supporting the differentiated safety profile, combinability with standard of care ...

"Cancer cells from patient's primary tumours that ended up relapsing in the liver or the lung early on adopt cellular states ...

SELLAS’s Phase 2 clinical trial for its investigational drug SLS009 for acute myeloid leukemia showed positive results.

BGB-16673 showed high overall response rates in relapsed/refractory CLL/SLL, with a notable 94.4% response at the 200-mg dose level. Safety analysis revealed that 95.6% of patients experienced ...

Aptevo Therapeutics (APVO) presented preliminary results from its ongoing Phase 1b/2 RAINIER study evaluating mipletamig, a CD123 x CD3 bispecific ...

CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML 31 ...

Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of ...